Atea Pharmaceuticals (AVIR) Accumulated Depreciation (2019 - 2025)

Atea Pharmaceuticals' Accumulated Depreciation history runs 7 years deep, the most recent figure standing at $1.5 million for Q4 2025.

• On a quarterly basis, Accumulated Depreciation rose 37.65% year-over-year to $1.5 million in Q4 2025; TTM through Dec 2025 was $1.5 million, a 37.65% increase from a year earlier, with the FY2025 full-year figure at $1.5 million, up 37.65% from the prior year.
• Accumulated Depreciation climbed to $1.5 million in Q4 2025 per AVIR's latest filing, from $1.1 million in the prior quarter.
• Across five years, Accumulated Depreciation topped out at $1.5 million in Q4 2025 and bottomed at $161000.0 in Q4 2021.
• The 5-year median for Accumulated Depreciation is $689000.0 (2023), against an average of $749800.0.
• Across the five-year window, Accumulated Depreciation climbed 21.97% in 2021 and jumped 152.38% in 2023, its largest moves.
• Year by year, Accumulated Depreciation stood at $161000.0 in 2021, then jumped by 69.57% to $273000.0 in 2022, then soared by 152.38% to $689000.0 in 2023, then soared by 60.38% to $1.1 million in 2024, then soared by 37.65% to $1.5 million in 2025.
• Per Business Quant, the three latest AVIR Accumulated Depreciation figures stand at $1.5 million (Q4 2025), $1.1 million (Q4 2024), and $689000.0 (Q4 2023).